Prospective randomized phase II trial with gemcitabine plus sunitinib versus gemcitabine alone in first-line therapy of metastatic or locally advanced pancreatic cancer.

Trial Profile

Prospective randomized phase II trial with gemcitabine plus sunitinib versus gemcitabine alone in first-line therapy of metastatic or locally advanced pancreatic cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Nov 2014

At a glance

  • Drugs Gemcitabine (Primary) ; Sunitinib (Primary)
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Acronyms CESAR
  • Most Recent Events

    • 04 Jun 2013 Primary endpoint 'Progression-free-survival-duration' has not been met according to results presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
    • 30 Nov 2011 Actual end date Nov 2011 added as reported by ClinicalTrials.gov.
    • 30 Nov 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top